PubMed Health⌕ Search

Biomedical subjects

C Dahlöf

Publications and source records attributed to C Dahlöf.

At least 55 records · Page 3Linked to original sources
PubMed1994

Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human unstimulated whole saliva flow rate and protein composition.

The effects of 1-wk medication with two beta-adrenoceptor antagonists on unstimulated whole saliva flow rate and protein composition were evaluated in 11 healthy young men in a randomized, double-blind, placebo-controlled, cross-over study. Unstimulated whole saliva was collected before each treatment period and then again after 7 days. The saliva was assessed for flow rate, total protein, and hexosamine and sialic acid concentrations and for amylase activity. No significant effect on saliva secretion rate was found. A statistically significant reduction of salivary total proteins was registered during atenolol medication. The amylase activity decreased significantly during treatment with both atenolol and propranolol. Significant changes of the calculated ratios of sialic acid/hexosamine and hexosamine/total protein indicated an alteration in glandular protein synthesis after atenolol treatment.

Adult↗
PubMed1994

Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human parotid and submandibular-sublingual salivary secretion.

The aim of the study was to evaluate the effects of a beta 1-selective (atenolol 50 mg q.d.) and a non-selective (propranolol 80 mg b.i.d.) beta-adrenoceptor antagonists on human stimulated parotid and submandibular-sublingual (SM-SL) gland secretion. A randomized double-blind, placebo-controlled cross-over ("Latin square") design was used in 19 healthy male volunteers. Stimulated parotid and SM-SL saliva were sampled immediately before and 7 days after the start of each treatment period. Stimulation of salivary secretion was achieved by use of a 3% citric acid solution. Plasma concentrations of propranolol and atenolol were determined from blood samples. The salivary secretion of both glands was assessed for flow rate, amylase, lysozyme, and salivary peroxidase activity and for concentrations of total protein, hexosamine, sialic acid, Ca2+, Cl-, K+, Mg2+, Na+, and PO4(3-). In both parotid and SM-SL secretions, the total protein and phosphate concentrations and amylase activity were significantly decreased during the two active treatment periods. In SM-SL gland secretion, there were significant changes in potassium and calcium concentrations during active treatment as compared with baseline, with potassium showing a decreased and calcium an increased concentration. During atenolol treatment, salivary peroxidase activity decreased significantly in SM-SL secretion. In parotid secretion, the hexosamine/total protein ratio decreased and the sialic acid/hexosamine ratio increased during atenolol treatment, which may indicate an effect on protein synthesis. No significant effects on salivary secretion rates were disclosed.

Adult↗
PubMed1993

Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine.

The aim of the present study was to assess the efficacy and tolerability of single oral doses of 50 mg and 100 mg of diclofenac-K compared to placebo in migraine sufferers during three attacks. The study was conducted in a double-blind, randomized, placebo-controlled, three-period, within-patient comparative trial; 72 migraine patients were treated with diclofenac-K (50 mg or 100 mg) or placebo at six centres (1 in Sweden and 5 in Finland). The primary efficacy end-point was the change in pain intensity assessed on a 100 mm Visual Analogue Scale (VAS) at 120 min after taking the study medication. We found that 50 mg and 100 mg of diclofenac-K reduced the pain intensity significantly better than placebo (p = 0.003 and p = 0.001, respectively), without difference between the doses; 100 mg diclofenac-K was significantly better than placebo in improving phonophobia, photophobia, working ability and need for rescue medication. Diclofenac-K 50 mg or 100 mg is an effective and well-tolerated acute treatment for migraine headache and its associated symptoms. The higher dose of diclofenac-K was only marginally more effective than the lower dose.

Adolescent↗
PubMed1993

Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine.

Although oral ergotamine alone or in combination with caffeine is widely used for the acute treatment of migraine, there is little evidence that it is significantly more effective than placebo. There are no placebo-controlled data to support the use of aerosol or suppository formulations. In addition, the recommended doses of ergotamine cannot be justified. Each formulation of ergotamine now should be tested in clinical studies performed according to the IHS criteria for trial design and in migraine patients fulfilling the diagnostic criteria of the IHS. Until these clinical data are available, no clear recommendations can be given for the use of ergotamine in the acute treatment of migraine.

Adolescent↗
PubMed1993

Assessment of health-related quality of life in migraine.

Assessment of HQL has become an important complement to the traditional methods that are used for objective registration of physiological, structural or biochemical processes during an illness. A generally applicable definition of HQL includes both subjective perception of one's life situation and objectively registrable health factors. This manner of evaluating quality of life perhaps will achieve further acceptance and thereby facilitate both reporting and evaluation of quality-of-life measurements. To document changes in HQL more precisely, reliable and valid test instruments with sufficient sensitivity to detect clinically relevant changes are essential. Available data indicate that the individual's personality, the migraine attack or its treatment or both can influence the patient's HQL. At present it is unclear which of the available acute treatments for migraine attacks produces the best general well-being or highest quality of life. It is probable that, as in other therapeutic areas, an optimal treatment result can only be achieved with an individualized therapeutic strategy.

Humans↗
PubMed1993

A modified device for collection and flow-rate measurement of submandibular-sublingual saliva.

The aims of the present study were to measure stimulated submandibular-sublingual (SM-SL) salivary flow rate with a modified Block-Brottman collection device, and, further, to evaluate the reliability of measurements of stimulated SM-SL salivary flow rate by means of this modified Block-Brottman device, as compared to measurements of parotid flow rate using modified Carlson-Crittenden cups. Twenty-nine healthy female volunteers, aged 36 +/- 7 yr, were included. Saliva stimulation was achieved by application of a 3% citric acid solution to the rims of the tongue four times/min, for 3 s every 15 s. On 3 consecutive days, stimulated parotid and SM-SL salivas were collected for 2 min at 07.30, before breakfast (morning value), and at 10.00, 2 h after a standard breakfast (lunchtime values). SM-SL saliva was also collected on one occasion for 2 min x 3. For parotid and SM-SL saliva, the mean stimulated flow rates were in the morning, 1.50 +/- 0.83 and 2.25 +/- 1.12 ml/min, and at lunchtime, 1.71 +/- 1.16 and 2.54 +/- 1.01 ml/min, respectively. For both salivas, lunchtime values were significantly higher than morning values by about 13-14%. Comparing parotid and SM-SL saliva flow rates, we found the SM-SL saliva flow rate to exceed the parotid flow rate by about 50% both in the morning and at lunchtime. Variations in flow rate were analyzed by means of ANOVA. Interindividual variance and variance between measurement days and times of day made up 88% of parotid and 83% of SM-SL total variance.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1993

Oral mucosal friction and subjective perception of dry mouth in relation to salivary secretion.

Assessment of oral mucosal friction and subjective perception of dry mouth was performed during treatment with thiazide diuretic bendroflumethiazide (2.5 mg o.d.) or placebo in a randomized, double-blind, cross-over study (2 x 2 wk) in 34 healthy volunteers. Treatment with bendroflumethiazide was associated with a 10% reduction in the stimulated whole saliva secretion rate and a 15% reduction in the salivary sodium concentration, as compared with placebo. Oral mucosal friction was concomitantly measured on the buccal mucosa and on the mucosa of the lower lip by means of a newly developed sliding friction device. In addition, a questionnaire was used to evaluate how the treatment was subjectively perceived with regard to symptoms of dry mouth. Mucosal friction of the lower lip increased significantly during treatment with bendroflumethiazide, as compared with placebo. When the test subjects, regardless of pharmacologic treatment, were divided into groups according to subjective perception of dry mouth, the dry mouth group showed significantly lower resting and stimulated flow rate and higher mucosal friction in comparison to the nondry group. When, in addition, pharmacologic treatment was also considered, the differences between the dry and the nondry group were restricted to resting whole saliva flow rate and mucosal friction during bendroflumethiazide treatment. It is concluded that resting whole saliva flow rate is the best predictive factor for evaluating subjectively perceived dry mouth. However, the sensitivity of the developed sliding friction device is capable of detecting minor changes in salivary secretion rate. In addition, measurements of oral mucosal friction may serve as an easily available method to complement sialometry when evaluating, for example, drug-induced dryness of the mouth.

Adolescent↗
PubMed1992

General well-being during treatment with different ACE-inhibitors: two double-blind placebo-controlled cross-over studies in healthy volunteers.

Two randomised, double-blind, cross-over studies in healthy volunteers given captopril 50 mg b.d. (n = 37; Study I) or enalapril 20 mg o.d. (n = 40; Study 2) and placebo for 2 weeks have been done to examine general well-being. Subjective experiences were evaluated using the standardised, Minor Symptoms Evaluation-profile (MSEP), which was completed during Run-in and on Days 1, 4, 7 and 14 in the morning. In comparison to placebo and the Run-in period, neither captopril nor enalapril affected the MSEP dimensions of Vitality, Contentment and Sleep. Captopril treatment was also assessed by applying the Quality of Life Clinical Questionnaire during Run-in and on Days 7 and 14. No improvement in the quality of life was demonstrated during treatment in comparison with the placebo or the Run-in period. Thus, no mood elevating effect of the ACE-inhibitors captopril and enalapril was demonstrated in healthy volunteers. Cough, which is believed to be a common adverse effect of ACE-inhibitors, was no more frequent during the treatment with captopril or enalapril than with placebo. It is concluded, that short-term treatment with captopril or enalapril is not perceived differently by healthy volunteers than placebo or no treatment at all. Furthermore, the cough associated with ACE-inhibition may be dependent on the duration of treatment, and two weeks was apparently too short for it to emerge.

Adult↗
PubMed1992

Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human whole saliva flow rate and composition.

The effects of beta-adrenoceptor antagonists on salivary secretion have been extensively studied in animals but not in man. The aim here was to compare salivary flow rate and composition in man during 1 week of treatment with a non-selective (propranolol 80 mg b.i.d.) and a beta 1-selective (atenolol 50 mg o.d.) antagonist with that of placebo. The randomized, double-blind, cross-over ("Latin square") design was used and 42 healthy male volunteers were recruited to the study. The treatment periods were separated by a wash-out period of 2 weeks. Whole saliva was sampled on day 0 (before) and on day 7 during each treatment. The plasma concentration of propranolol and atenolol was determined from blood samples obtained on day 7. Resting saliva was assessed for flow rate, amylase activity and concentration of total protein, hexosamine and sialic acid. Stimulated saliva was assessed for flow rate, pH, buffer pH, amylase activity and concentration of total protein, Ca2+, Mg2+, Na+, K+, Cl- and PO4(2-). In resting as well as stimulated whole saliva both the total protein concentration and the amylase activity were significantly decreased during the active treatment periods (p less than 0.05-p less than 0.001). At lunchtime during atenolol treatment the hexosamine/total protein and the sialic acid/total protein ratios were significantly increased (p less than 0.05-p less than 0.01), suggesting a possible effect on protein synthesis. In addition, the concentrations of Ca2+, PO4(2-), Cl- and Mg2+ were significantly altered during the active treatment periods (p less than 0.05-p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1992

Cytochrome P-450-dependent hydroxylation in migraine.

The hypothesis was tested that an acute oxidation deficiency related to potential dietary trigger factors plays a role in the migraine attack. Migraine sufferers (14F and 4M), fulfilling the criteria for migraine with and without aura according to the classification of the International Headache Society, were coadministered oral mephenytoin (100 mg) and debrisoquine (10 mg) during the initial phase of a typical migraine attack. This was repeated during a period without migraine. The hydroxylation of mephenytoin and debrisoquine hydroxylation did not differ during and without the migraine attack. We conclude that hydroxylation, via cytochrome P-450 (2D6, 2C8 and 9), is not reduced during the migraine attack. The results do not support the hypothesis that oxidation deficiency is involved in the pathophysiology of migraine.

Chromatography, Gas↗
PubMed1992

Sumatriptan injection is superior to placebo in the acute treatment of migraine--with regard to both efficacy and general well-being.

The efficacy of subcutaneous injection of sumatriptan in the acute treatment of migraine was assessed in a double-blind, randomized, placebo-controlled cross-over study of 27 migraine patients. In addition, the patients were asked to give information about their well-being and subjective symptoms by means of a self-administered standardized questionnaire. A total of 22 migraine sufferers received a subcutaneous (sc) injection of 8 mg of sumatriptan and 24 received placebo. Of these patients, 19 received both treatments and thus completed the study. The primary efficacy end-point was a reduction in headache severity from severe or moderate to mild or no headache at 30, 60, 90 and 120 min. An effective response to treatment was achieved within 30 min in 63% and within 60 min in 84% of patients when treated with 8 mg sumatriptan sc, compared with 11% for placebo (p less than 0.001). Sumatriptan also provided significant relief from nausea and photophobia as compared with placebo. The proportion of patients that needed rescue medication after 120 min was significantly lower (p less than 0.001) with active treatment when compared with placebo. Sumatriptan was well tolerated and the majority of adverse events were mild and transient. The most frequent symptoms were those of malaise/fatigue or numbness. No changes in blood pressure or ECG readings were observed during the treatment. Compared with placebo, subcutaneous 8 mg sumatriptan also caused a substantial improvement in general well-being as revealed by the Minor Symptoms Evaluation Profile-acute (MSEP-acute) questionnaire.(ABSTRACT TRUNCATED AT 250 WORDS)

Acute Disease↗
PubMed1991

D-myo-inositol-1,2,6-trisphosphate is a selective antagonist of neuropeptide Y-induced pressor responses in the pithed rat.

The antagonistic effects of a new inositol phosphate derivative, D-myoinositol-1,2,6-trisphosphate (PP56), on pressor responses to preganglionic sympathetic nerve stimulation and exogenously administered phenylephrine or neuropeptide Y (NPY) were investigated in vivo in the pithed rat. In this model an intravenous (i.v.) bolus administration of PP56 (1-50 mg/kg) dose dependently inhibited the increase in mean arterial blood pressure (MAP) induced by a continuous infusion of NPY (2 micrograms/kg per min for 10 min). PP56 in a dose of 5 mg/kg i.v. bolus reduced the entire NPY dose-response curve (0.4-8 microgram/kg per min 10 min infusion) without any shift to the right indicating a non-competitive interaction. Furthermore, PP56 (10-50 mg/kg i.v.) was found to inhibit the pressor response to preganglionic sympathetic nerve stimulation and i.v. bolus injection of the alpha 1-adrenoceptor agonist, phenylephrine. The dose-response curves for increasing doses of phenylephrine and incremental preganglionic sympathetic nerve stimulation were not significantly altered by a lower dose of PP56 (5 mg/kg i.v. bolus). We conclude that PP56, representing a new class of synthetic drugs, can antagonize the actions of exogenous and endogenous NPY in vivo, an action which is specific for NPY within a limited dose range.

Analysis of Variance↗